



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	GHK-Cu
Lot / Batch	RVA-CU-805A17	Label Claim	50 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	White
Crimp Color	Silver / Aluminum	Contents Color	Blue
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
GHK-Cu intact-complex identity (HILIC-ESI-MS) research screen	sample response within 402.11 m/z $\pm$ 1.00 Da (inclusive 401.11–403.11 m/z) · 402.11 m/z for [L+Cu-H] ⁺ (published intact-complex identity context only — not a formula-derived mass and not the sample acceptance target), source https://doi.org/10.3390/molecules28186724	402.117 m/z; matched-standard difference +0.007 Da	PASS
Purity validated in house	$\geq$ 99.25 area %	99.54%	PASS
Net Peptide Content research screen	every vial within $\pm$ 10% of 50 mg	Vial A: 51.93 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:d4bc6415f022b401e2ae2de1...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:68595a2bf9153d9aa401adc4...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:66409614cafc77ae4c89cfe1...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-4190-2DH2>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: c40fc3335b7e7b1482f7fd2b26c8297dbcadcc40d671db179c745dc17a72f985...

Seal: ed25519:927e92caf8a885e9c85178a10bf73bdd1e3d8803...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity


■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

Brand	Latitude 40 Aminos	Product	GHK-Cu
Lot / Batch	RVA-CU-805A19	Label Claim	100 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Clear
Crimp Color	Silver / Aluminum	Contents Color	Blue
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



MORE VIEWS OF VIAL A



Vial A - right

Test Results

Test	Specification	Result	
GHK-Cu intact-complex identity (HILIC-ESI-MS) research screen	sample response within 402.11 m/z $\pm$ 1.00 Da (inclusive 401.11–403.11 m/z) · 402.11 m/z for [L+Cu-H] ⁺ (published intact-complex identity context only — not a formula-derived mass and not the sample acceptance target), source https://doi.org/10.3390/molecules28186724	402.108 m/z; matched-standard difference -0.002 Da	PASS
Purity validated in house	$\geq$ 99.25 area %	99.97%	PASS
Net Peptide Content research screen	every vial within $\pm$ 10% of 100 mg	Vial A: 105.25 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1

GHK-Cu intact-complex identity (HILIC-ESI-MS)
HILIC-ESI-MS intact GHK-Cu full-scan/isotope identity

402.108 m/z; matched-standard difference -0.002 Da

sample response within 402.11 m/z $\pm$ 1.00 Da (inclusive 401.11–403.11 m/z) · 402.11 m/z for [L+Cu-H]⁺ (published intact-complex identity context only — not a formula-derived mass and not the sample acceptance target), source <https://doi.org/10.3390/molecules28186724>

PASS

Result

402.108 m/z; matched-standard difference -0.002 Da

Acceptance

sample response within 402.11 m/z $\pm$ 1.00 Da (inclusive 401.11–403.11 m/z) · 402.11 m/z for [L+Cu-H]⁺ (published intact-complex identity context only — not a formula-derived mass and not the sample acceptance target), source <https://doi.org/10.3390/molecules28186724>

2

Purity
HILIC-CAD homogeneity (universal detection)

99.97%

$\geq$ 99.25 area %

PASS

Acceptance

$\geq$ 99.25%

Vial A

99.97% · PASS

Criterion

Axiom Analytics SPEC-PURITY-001, Revision 1, effective

source

2026-08-31

3

Net Peptide Content
Quantitative HPLC vs reference std

Vial A: 105.25 mg

every vial within $\pm$ 10% of 100 mg

PASS

Target

100 mg ($\pm$ 10%)

Vial A

105.25 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

4

Sterility · Rapid PCR
Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen

Target panel

Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA gene (FAM)

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:b3720b8d4b2f76454b747834...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:e56be0aee3986b772834d283...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:6a4689cd75bf5f7e9b27e4bb...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-2112-4DP2>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: eea9670d8820bdb029ccdcf7249e47599dcfa48dc8c20f1d78351bd19f4110...

Seal: ed25519:75a47e923470eaf80bb6c0f90e067c5a139a4121...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.



Client Latitude 40 Aminos

Analyzed 08/10/2026

This Certificate of Analysis certifies that the sample listed herein was tested by SteriGenix using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	GHK-Cu (Copper Peptide)	Form	Lyophilized
Batch	SGX-L4A-2026-0727-L73	Labeled Qty	100MG
Mol. Formula	C14H22CuN6O4	CAS Number	89030-95-5
Cap Color	Blue	Crimp Color	Silver
Appearance	Blue Powder		

TEST RESULTS

	REFERENCE STANDARD	RESULT	
Identity Confirmation (LC-MS)	GHK-Cu (Copper Peptide)	GHK-Cu (Copper Peptide)	✓
Batch Avg Purity (HPLC)	(>98%)	99.91	✓
Net Peptide Content	100MG ± 10%	101.74	✓


HEAVY METAL SCREENING

No data.

BATCH CONFORMITY RESULTS

No data.

HPLC CHROMATOGRAM



SAMPLE PHOTOS



AS RECEIVED

RECONSTITUTED (BACT. WATER) — CLARITY
CHECK

Dr. R. Caldwell

ANALYST
ID: AN-3271

Dr. P. Andersen

QC REVIEWER
ID: QR-5418

Dr. H. Whitman

QA DIRECTOR
ID: QA-1090



sterigenixanalytical.com/verify

Report#: RPT-2026-196581
Access Code: SGX-L4A-2026-0727-L73

